Alkermes plc (NASDAQ:ALKS) Shares Sold by Vontobel Holding Ltd.

Vontobel Holding Ltd. decreased its holdings in Alkermes plc (NASDAQ:ALKS - Free Report) by 14.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 48,279 shares of the company's stock after selling 7,982 shares during the period. Vontobel Holding Ltd.'s holdings in Alkermes were worth $1,389,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also modified their holdings of the stock. Loomis Sayles & Co. L P grew its stake in Alkermes by 365.5% during the 3rd quarter. Loomis Sayles & Co. L P now owns 1,882,936 shares of the company's stock worth $52,704,000 after purchasing an additional 1,478,422 shares in the last quarter. Frazier Life Sciences Management L.P. purchased a new position in shares of Alkermes in the 3rd quarter valued at about $16,126,000. Barclays PLC grew its position in shares of Alkermes by 108.8% during the third quarter. Barclays PLC now owns 423,931 shares of the company's stock worth $11,867,000 after buying an additional 220,893 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Alkermes by 55.4% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 405,382 shares of the company's stock worth $11,347,000 after buying an additional 144,506 shares in the last quarter. Finally, Edgestream Partners L.P. increased its stake in shares of Alkermes by 218.4% during the third quarter. Edgestream Partners L.P. now owns 270,671 shares of the company's stock worth $7,576,000 after buying an additional 185,648 shares during the period. Hedge funds and other institutional investors own 95.21% of the company's stock.

Insider Buying and Selling

In other Alkermes news, EVP Craig C. Hopkinson sold 144,419 shares of Alkermes stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $35.53, for a total value of $5,131,207.07. Following the transaction, the executive vice president now directly owns 57,875 shares in the company, valued at approximately $2,056,298.75. This trade represents a 71.39 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Christian Todd Nichols sold 5,208 shares of the business's stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $29.15, for a total value of $151,813.20. Following the completion of the transaction, the senior vice president now directly owns 60,703 shares in the company, valued at approximately $1,769,492.45. The trade was a 7.90 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 323,608 shares of company stock valued at $10,854,725 over the last quarter. 4.89% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research analysts have commented on the stock. Piper Sandler reiterated an "overweight" rating and set a $37.00 price target (down previously from $38.00) on shares of Alkermes in a report on Friday, October 25th. Stifel Nicolaus upgraded shares of Alkermes from a "hold" rating to a "buy" rating and boosted their target price for the stock from $25.00 to $36.00 in a research note on Tuesday, November 5th. The Goldman Sachs Group increased their target price on Alkermes from $30.00 to $32.00 and gave the company a "buy" rating in a report on Friday, February 14th. Mizuho lifted their price target on Alkermes from $35.00 to $40.00 and gave the stock an "outperform" rating in a report on Wednesday, November 13th. Finally, Cantor Fitzgerald dropped their price objective on Alkermes from $48.00 to $43.00 and set an "overweight" rating on the stock in a report on Friday, October 25th. Two analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $38.36.

Alkermes Stock Down 0.5 %

ALKS traded down $0.17 during trading on Friday, hitting $35.33. 1,062,582 shares of the stock were exchanged, compared to its average volume of 1,711,444. The firm has a market capitalization of $5.74 billion, a P/E ratio of 16.28, a PEG ratio of 2.23 and a beta of 0.49. Alkermes plc has a 1-year low of $22.90 and a 1-year high of $36.45. The stock has a fifty day moving average price of $30.79 and a two-hundred day moving average price of $29.02.

Alkermes (NASDAQ:ALKS - Get Free Report) last announced its earnings results on Wednesday, February 12th. The company reported $0.92 EPS for the quarter, beating analysts' consensus estimates of $0.81 by $0.11. Alkermes had a net margin of 23.57% and a return on equity of 30.80%. Analysts predict that Alkermes plc will post 1.31 EPS for the current year.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.